Randox at AACC 2018 - Booth #3624

Location : McCormick Place, Chicago, Illinois
  Date : July 31st - August 2nd 2018

Molecular

Randox Biosciences offers diagnostic, prognostic and predictive solutions across a variety of disease areas including sexually transmitted infection, cardiovascular disease (CVD), familial hypercholesterolemia (FH), colorectal cancer and respiratory infection.

We offer a wide range of assay formats including SNP genotyping, pathogen detection and mutation detection, optimised for use with the Randox Evidence Investigator semi-automated bench top biochip analyser, for improved laboratory efficiency

 

Familial Hypercholesterolemia (FH) Arrays I & II

Developed with leading experts to test for 40 specific FH-causing mutations including LDLR, ApoB and PCSK9 with ~78% coverage, providing a targeted, cost-effective assay for FH testing. Rapid turnaround time allows same day reporting, compared to lengthy NGS screening which can take weeks or months to report results. The test consists of two mutation arrays, allowing for single biochip testing in cases of cascade screening of known mutations for further laboratory cost savings

 

Cardiac
Risk Array

The Cardiac Risk Prediction Array from Randox Biosciences allows 20 SNPs to be genotyped simultaneously. The genotype information is then processed within an algorithm which weights each SNP and calculates CHD genetic risk. This information is combined with common risk factors and an overall CHD risk score is generated.

 

Respiratory Multiplex Array

The test simultaneously identifies 22 of the most prevalent respiratory viral and bacterial infections.  The array provides a rapid and more cost- effective diagnostic approach than current tests that detect single pathogens only.

 

STI Multiplex
Array

The test simultaneously detects 10 of the most common sexually transmitted infections to provide a complete infection profile. The array detects primary, secondary and asymptomatic co-infections in a single test for a comprehensive and cost-effective screen.

KRAS, BRAF, PIK3CA* Array

The test simultaneously detects 20 mutations within the most common genes implicated in colorectal cancer, offering an efficient and cost-effective approach for determining mutational status and patient response to therapy.